What does VABO PHARMA do?

VABO PHARMA is a pharmacy in Menen. Private Limited, started on 2 January 1980, 1 establishment.

What is the address of VABO PHARMA?

The registered office of VABO PHARMA is located at Dronckaertstraat 68 B, 8930 Menen.

Is VABO PHARMA still active?

Yes. According to the CBE (29 October 2026) VABO PHARMA is active, legal situation “Normale toestand”, started on 2 January 1980.

Is VABO PHARMA registered on Peppol?

Yes, VABO PHARMA is registered on the Peppol network with ID 0208:0420027816.

What is the enterprise number of VABO PHARMA?

The enterprise number of VABO PHARMA is BE0420027816.

When was VABO PHARMA founded?

VABO PHARMA was founded on 2 January 1980.

Who are the directors of VABO PHARMA?

According to the 2025 annual accounts, the directors of VABO PHARMA are: JUVENTAS & ASSOCIES SCOMM, BEHEER FIEBEY COMMV.

Is VABO PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 2 January 1980; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did VABO PHARMA make in 2025?

VABO PHARMA posted a profit after taxes of € 30,624 in financial year 2025.

What is the revenue of VABO PHARMA?

As a small company, VABO PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 372,287.

How much does an employee at VABO PHARMA earn?

The average wage cost per full-time employee at VABO PHARMA was € 67,800 in 2025: staff costs of € 210,055 for 3.1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does VABO PHARMA have?

According to the 2025 annual accounts, VABO PHARMA has 3.1 full-time equivalents (FTE).

VABO PHARMA (Private Limited) - Menen - BE0420027816

Dossier VABO PHARMA, printed on 29 October 2026 from databakkes.be/en/0420027816/vabo-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 36 % of short-term debt in 2025; threshold 65 %.
Shrinking team NBB

FTE fell two years in a row, from 3.9 to 3.1.

Financials

Financial year 2025

VABO PHARMA from Menen, company number BE0420027816, closed financial year 2025 with a result of € 30,624 after tax. For that financial year VABO PHARMA recorded a gross margin of € 372,287 and equity of € 166,233. Compared with financial year 2024, the result moved from € 139,286 to € 30,624. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 23, 2026.

What it is worth Growing

€ 166,233

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 30,624

▼ 78% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 65,108

▼ 34% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 30,000 paid out

98 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Full-time equivalents

3.1

▼ 0.4 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 210,055

▼ 8% vs 2024

€ 67,800 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 1,609

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 12,248

▼ 97% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 159,986

▲ 16% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 24,571

▼ 37% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 697,150 Gross margin 2022: € 697,150 First fiscal year in the series	€ 602,264 Gross margin 2023: € 602,264 ▼ 14% vs 2022 (€ 697,150) Unfavourable step	€ 451,116 Gross margin 2024: € 451,116 ▼ 25% vs 2023 (€ 602,264) Unfavourable step	€ 372,287 Gross margin 2025: € 372,287 ▼ 17% vs 2024 (€ 451,116) Unfavourable step	▼ 17%
Profit after taxes	€ 329,894 Profit after taxes 2022: € 329,894 First fiscal year in the series	€ 267,690 Profit after taxes 2023: € 267,690 ▼ 19% vs 2022 (€ 329,894) Unfavourable step	€ 139,286 Profit after taxes 2024: € 139,286 ▼ 48% vs 2023 (€ 267,690) Unfavourable step	€ 30,624 Profit after taxes 2025: € 30,624 ▼ 78% vs 2024 (€ 139,286) Unfavourable step	▼ 78%
Equity	€ 158,632 Equity 2022: € 158,632 First fiscal year in the series	€ 161,323 Equity 2023: € 161,323 ▲ 2% vs 2022 (€ 158,632) Favourable step	€ 165,609 Equity 2024: € 165,609 ▲ 3% vs 2023 (€ 161,323) Favourable step	€ 166,233 Equity 2025: € 166,233 Unchanged (€ 165,609) Favourable step
Total debts	€ 1,491,313 Total debts 2022: € 1,491,313 First fiscal year in the series	€ 1,244,210 Total debts 2023: € 1,244,210 ▼ 17% vs 2022 (€ 1,491,313) Favourable step	€ 903,296 Total debts 2024: € 903,296 ▼ 27% vs 2023 (€ 1,244,210) Favourable step	€ 794,580 Total debts 2025: € 794,580 ▼ 12% vs 2024 (€ 903,296) Favourable step	▼ 12%
Cash	€ 21,814 Cash 2022: € 21,814 First fiscal year in the series	€ 51,439 Cash 2023: € 51,439 ▲ 136% vs 2022 (€ 21,814) Favourable step	€ 99,025 Cash 2024: € 99,025 ▲ 93% vs 2023 (€ 51,439) Favourable step	€ 65,108 Cash 2025: € 65,108 ▼ 34% vs 2024 (€ 99,025) Unfavourable step	▼ 34%
Land & buildings	€ 466,869 Land & buildings 2022: € 466,869 First fiscal year in the series	€ 444,070 Land & buildings 2023: € 444,070 ▼ 5% vs 2022 (€ 466,869) Unchanged	€ 414,278 Land & buildings 2024: € 414,278 ▼ 7% vs 2023 (€ 444,070) Unchanged	€ 384,875 Land & buildings 2025: € 384,875 ▼ 7% vs 2024 (€ 414,278) Unchanged	▼ 7%
Retained profit	€ 108,632 Retained profit 2022: € 108,632 First fiscal year in the series	€ 111,323 Retained profit 2023: € 111,323 ▲ 2% vs 2022 (€ 108,632) Favourable step	€ 115,609 Retained profit 2024: € 115,609 ▲ 4% vs 2023 (€ 111,323) Favourable step	€ 116,233 Retained profit 2025: € 116,233 ▲ 1% vs 2024 (€ 115,609) Favourable step	▲ 1%
Dividend	€ 325,000 Dividend 2022: € 325,000 First fiscal year in the series	€ 265,000 Dividend 2023: € 265,000 ▼ 18% vs 2022 (€ 325,000) Unchanged	€ 135,000 Dividend 2024: € 135,000 ▼ 49% vs 2023 (€ 265,000) Unchanged	€ 30,000 Dividend 2025: € 30,000 ▼ 78% vs 2024 (€ 135,000) Unchanged	▼ 78%
Bank debt	€ 641,422 Bank debt 2022: € 641,422 First fiscal year in the series	€ 502,041 Bank debt 2023: € 502,041 ▼ 22% vs 2022 (€ 641,422) Favourable step	€ 362,829 Bank debt 2024: € 362,829 ▼ 28% vs 2023 (€ 502,041) Favourable step	€ 12,248 Bank debt 2025: € 12,248 ▼ 97% vs 2024 (€ 362,829) Favourable step	▼ 97%
Balance sheet total	€ 1,649,945 Balance sheet total 2022: € 1,649,945 First fiscal year in the series	€ 1,405,533 Balance sheet total 2023: € 1,405,533 ▼ 15% vs 2022 (€ 1,649,945) Unchanged	€ 1,068,905 Balance sheet total 2024: € 1,068,905 ▼ 24% vs 2023 (€ 1,405,533) Unchanged	€ 960,813 Balance sheet total 2025: € 960,813 ▼ 10% vs 2024 (€ 1,068,905) Unchanged	▼ 10%
Employees (FTE)	4.9 Employees (FTE) 2022: 4.9 First fiscal year in the series	3.9 Employees (FTE) 2023: 3.9 ▼ 1 vs 2022 (4.9) Unchanged	3.5 Employees (FTE) 2024: 3.5 ▼ 0.4 vs 2023 (3.9) Unchanged	3.1 Employees (FTE) 2025: 3.1 ▼ 0.4 vs 2024 (3.5) Unchanged	▼ 0.4

Key figures of VABO PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to VABO PHARMA?

What happened at VABO PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 23, 2026 New annual accounts for financial year 2025: profit of € 30,624 (▼ 78% vs 2024). Source: NBB ↗
2011 JUVENTAS & ASSOCIES SCOMM became a director. NBB
2011 BEHEER FIEBEY COMMV became a director. NBB
Jan 24, 1980 New establishment in Menen. KBO
Jan 2, 1980 Start of the company according to the CBE. KBO

In short

From € 329,894 profit in 2022 to € 30,624 profit in 2025.

Paid € 14,043 in corporate taxes since 2022.

Best year ever: 2022, with € 329,894 profit.

On average € 120,100 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

JUVENTAS & ASSOCIES SCOMM BEHEER FIEBEY COMMV

De Rote

LEIEZICHT

SENIORIE STEPHANIE

VABO PHARMA

+29

Behind VABO PHARMA are JUVENTAS & ASSOCIES SCOMM and BEHEER FIEBEY COMMV. The same people are also behind De Rote, LEIEZICHT, SENIORIE STEPHANIE, RUSTHUIS STRIJLAND and DAYAM. BEHEER FIEBEY COMMV is also behind DIKI RECORDS, DEWOFIRE, R.A.S.R. 11, Flanders Lease Renting & Trade and HYSOP.

Directors

According to the 2025 annual accounts

JUVENTAS & ASSOCIES SCOMM

Director · represented by Gaënne Fievez

Also active at: De Rote, LEIEZICHT, SENIORIE STEPHANIE, RUSTHUIS STRIJLAND, DAYAM, RESIDENCE MARIE - ASTRID, ACROPOLYS, PHIBA +19 more

since 2011

BEHEER FIEBEY COMMV

Director · represented by Thierry Fievez

Also active at: De Rote, LEIEZICHT, SENIORIE STEPHANIE, RUSTHUIS STRIJLAND, DAYAM, RESIDENCE MARIE - ASTRID, ACROPOLYS, PHIBA +24 more

since 2011

Establishments

Establishment units

Physical locations of this company

Registered office

Dronckaertstraat 68 B

8930 Menen

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0420.027.816

VAT number

BE 0420.027.816

Registered office

Dronckaertstraat 68 B, 8930 Menen

Names & denominations

VABO PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

2 January 1980

Peppol

Active · Active since 11 Mar 2025

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

Detailhandel in cosmetica en toiletartikelen

View on CBE Public ↗ Annual accounts (NBB) ↗

VABO PHARMA

Warning lights

Financials

What happened to VABO PHARMA?

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions